{"id":2616,"date":"2018-12-01T12:04:00","date_gmt":"2018-12-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/demenz-bei-patienten-mit-m-parkinson-kombination-von-antidementiva-und-anticholinergika-unguenstig"},"modified":"2022-03-17T14:13:50","modified_gmt":"2022-03-17T13:13:50","slug":"demenz-bei-patienten-mit-m-parkinson-kombination-von-antidementiva-und-anticholinergika-unguenstig","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/demenz-bei-patienten-mit-m-parkinson-kombination-von-antidementiva-und-anticholinergika-unguenstig","title":{"rendered":"Demenz bei Patienten mit M. Parkinson: Kombination von Antidementiva und Anticholinergika ung\u00fcnstig"},"content":{"rendered":"<p>In Europa leiden > 1 Mio. Menschen an M. Parkinson. Bei 38% der Betroffenen tritt innerhalb von 10 Jahren nach Diagnosestellung eine Demenz auf (Demenz bei idiopathischem Parkinson-Syndrom; engl.: Parkinson&#8217;s Disease Dementia = PDD; 1) und laut Leitlinie der deutschen Gesellschaft f\u00fcr Neurologie (DGN) erreichen 48-80% der Patienten im Krankheitsverlauf das Stadium einer Demenz (2). [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In Europa leiden > 1 Mio. Menschen an M. Parkinson. Bei 38% der Betroffenen tritt innerhalb von 10 Jahren nach Diagnosestellung eine Demenz auf (Demenz bei idiopathischem Parkinson-Syndrom; engl.: Parkinson&#8217;s Disease Dementia = PDD; 1) und laut Leitlinie der deutschen Gesellschaft f\u00fcr Neurologie (DGN) erreichen 48-80% der Patienten im Krankheitsverlauf das Stadium einer Demenz (2). [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5143,5146,980,618,5145,776,5148,3269,5144,5147,3808,758,5142,2055,913,4314,744,2417,914,1069,2413,3928,1231,1438,2426,5150,405,639,1709,2425,922,5149,3689,905,1229,1351,2406,5141],"class_list":["post-2616","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acb","tag-acetylcholinestrase-hemmer","tag-amantadin","tag-amitriptylin","tag-anticholinergic-burden-score","tag-anticholinergika","tag-antidementiva","tag-atropin","tag-azetylcholinesterase-hemmer","tag-belladonna","tag-biperiden","tag-carbamazepin","tag-chlorpheniramin","tag-clomipramin","tag-clozapin","tag-darifenacin","tag-demenz","tag-dimenhydrinat","tag-diphenhydramin","tag-donepezil","tag-doxylamin","tag-fesoterodin","tag-galantamin","tag-m-parkinson","tag-maprotilin","tag-metixen","tag-olanzapin","tag-orphenadrin","tag-oxcarbazepin","tag-oxybutynin","tag-paroxetin","tag-procyclidin","tag-propiverin","tag-quetiapin","tag-rivastigmin","tag-solifenacin","tag-tolterodin","tag-trospium"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2616"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2616\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}